(Reuters) -AN2 Therapeutics said on Monday it will pause further enrollment in a mid-to-late-stage study testing its experimental drug to treat a type of bacterial lung infection, citing potentially lower-than-expected efficacy.
It clarified the pause was not due to any safety concerns.
The company was conducting a mid-stage study testing epetraborole, a once-daily oral drug to treat MAC lung disease, caused by bacterial infection.
AN2 said the decision to pause enrollment will give time to further evaluate the study data and it expects to announce top-line results from the study in the summer.
(Reporting by Mariam Sunny And Sneha S K in Bengaluru ; Editing by Krishna Chandra Eluri)
Comments